When an FDA inspector walks into your clinical trial operations — whether at your sponsor offices, a CRO facility, or a clinical site — they bring a checklist of questions that has been largely unchanged for decades. What were the study procedures? Who made which decisions, and when? What does the audit trail show?
Now add AI to that picture. Your protocol design was informed by a machine learning model that analyzed comparable trial failures. Your site selection algorithm identified high-enrolling sites. Your data review tool flags potential protocol deviations before a human reviewer sees them. Your safety monitoring software synthesizes adverse event narratives for the medical monitor’s review.
Can you explain and document each of those AI contributions in a way that satisfies an FDA inspection? Do your vendor contracts give you the access you would need? And have you addressed the fundamental reproducibility problem that makes generative AI outputs particularly difficult to defend in a regulatory context?
These are not hypothetical questions. They are the operational reality that FDA’s January 2025 draft guidance on AI in drug development — and the broader inspection framework that has always governed clinical trials — now require sponsors to answer.
What FDA’s Credibility Framework Requires for Clinical Trial AI
FDA’s January 2025 draft guidance titled Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products applies to AI models used to produce data or information that supports regulatory decision-making about drug safety, efficacy, or quality. Clinical trials sit squarely within that scope.
This means that when AI contributes to a clinical trial in a way that generates data or analysis used in a regulatory submission — an NDA, BLA, or post-market report — the AI model needs to satisfy FDA’s credibility assessment framework. That framework requires, at a minimum: a defined context of use, a risk-based credibility assessment plan, and documentation sufficient for a reviewer or inspector to evaluate whether the AI’s contribution was trustworthy.
But the credibility framework is not the only standard that applies to clinical trial AI. The inspection framework for GCP (Good Clinical Practice) compliance under 21 CFR Parts 312 and 812, and the computerized systems requirements under 21 CFR Part 11, all apply simultaneously. Clinical trial AI operates at the intersection of these overlapping regimes — and most of them were written before modern AI existed, which creates specific gaps that companies must navigate.
AI in Protocol Design: What Validation Looks Like
AI is being used increasingly in clinical trial protocol design — predicting optimal endpoints, estimating statistical power, selecting dose levels, modeling patient dropout rates, and analyzing historical trial data to identify protocol features associated with failure.
FDA’s inspection posture toward this use case depends on the specific function. If an AI model was used to inform a decision that a human sponsor ultimately made — and the submission reflects that human decision, supported by documented human reasoning — the AI’s role may be treated as background analysis rather than a regulated AI application requiring formal credibility documentation.
If, however, the AI output directly generates data or analysis that appears in the submission — a simulated patient population, a modeled dose-response curve used to justify the selected dose, a statistical analysis plan generated in part through AI drafting tools — the credibility framework applies. The sponsor must be able to demonstrate that the AI’s contribution was trustworthy for that specific context of use.
Validation for protocol design AI typically involves:
Historical performance analysis. How accurate has the model been in predicting outcomes for comparable trial designs? Can the sponsor produce evidence of the model’s performance on trials outside its training set?
Assumption documentation. AI protocol design tools embed assumptions about patient populations, standard of care, dropout rates, and other variables. Those assumptions must be documented and scrutinized. If the model was trained on a dataset of trials from a prior decade or a different geographic market, the assumption that its predictions translate to a current trial needs to be defended.
Human decision logging. When AI informs a protocol design decision, the record should reflect the human decision-maker’s assessment — including any ways in which the human departed from or modified the AI’s recommendation and why. “The model said X and we did X” is a less defensible record than “the model generated option X, we evaluated it against factors A, B, and C, and selected modified approach Y for reasons documented here.”
The Reproducibility Problem with Generative AI
Protocol design is increasingly one of the most acute areas of AI-related compliance risk because it is exactly where generative AI tools — large language models — are being adopted most rapidly.
Sponsors are using LLMs to draft protocol sections, synthesize literature, generate statistical analysis plan language, and produce investigator brochure summaries. These applications raise a reproducibility problem that does not arise with traditional deterministic software.
Generative AI models are stochastic: given identical inputs, they often produce different outputs depending on random initialization parameters, temperature settings, and other non-deterministic factors. This means that if an FDA inspector asks “show me how this section of the protocol was generated,” a sponsor cannot necessarily run the same prompt through the same model and get the same output. The moment of generation is effectively non-reproducible.
Under FDA’s framework, this creates a specific documentation obligation: the output — the actual text or analysis generated by the AI — must be captured and preserved at the time of generation. It is not sufficient to preserve only the prompt and the model version. The output itself must be part of the audit trail, because it is the output that was used, and the output cannot be reconstructed after the fact.
This is a significant operational departure from how many organizations are currently using AI writing tools. Most document management systems capture final documents, not AI-generated drafts. Most LLM interfaces do not automatically log every output. Sponsors using generative AI in clinical trial documentation need to implement explicit output-capture workflows — capturing and versioning AI-generated text at the time of generation, logging the model version and key parameters, and maintaining the relationship between input prompts and outputs throughout the document’s development.
FDA’s computerized systems guidance (21 CFR Part 11 and its companion guidance on computerized systems used in clinical trials) requires that audit trails capture the date and time of entries and changes, record who made each change, and allow reconstruction of the history of any record. Generative AI outputs that enter the documentation chain must be traceable through that system.
What an FDA Inspector Will Ask
FDA clinical trial inspectors — whether conducting Bioresearch Monitoring (BIMO) inspections of sponsors, CROs, or clinical sites — are trained to follow the data. They start with source documents and trace forward through the trial record to verify that what was submitted reflects what actually happened.
In the AI context, this translates to a predictable set of questions:
What AI tools were used in this trial, and what did they do? Inspectors will ask for an inventory of AI tools used in any aspect of the trial that touches regulated data — protocol development, data collection, data management, safety review, endpoint adjudication. Companies that cannot produce this inventory have an immediate inspection problem.
Who was responsible for each AI-informed decision? Under GCP, a human investigator or sponsor representative must be accountable for every significant trial decision. “The algorithm decided” is not an answer. The inspection record must reflect the name and role of the person who reviewed the AI output and took responsibility for the decision.
What validation was performed on the AI tool? For any AI tool that touched regulated clinical data, inspectors will ask for validation documentation. This includes qualification testing, system validation records, and evidence that the tool performed as expected in the trial setting.
Can you produce the complete audit trail? Under 21 CFR Part 11, audit trails for electronic records in clinical trials must be complete, unalterable, and accessible. For AI-assisted records, the audit trail must capture not just human actions but AI-generated content that entered the record, including the version of the AI model used.
What did the vendor provide? If a third-party AI tool was used, inspectors will ask whether the sponsor has the validation documentation, audit trail access, and model change notification records that the vendor was contractually required to provide.
What Clinical Trial AI Vendor Contracts Must Include
This last point — vendor documentation — is where many clinical trial sponsors are most exposed. Most commercial AI tools deployed in clinical trials are provided under standard software-as-a-service agreements that were not designed for FDA-regulated environments. Those agreements typically do not contain the provisions that FDA inspection readiness requires.
Based on FDA’s framework and established GCP principles, clinical trial AI vendor contracts need to address the following:
Validation documentation. The vendor must provide documentation sufficient for the sponsor to assess whether the AI tool has been validated for the specific use in the trial. This includes training data description, performance metrics, known limitations, and the scope of validation performed. For GCP-regulated applications, the sponsor cannot simply accept the vendor’s assurance that the tool works — the sponsor needs the documentation to demonstrate that it exercised appropriate oversight.
Audit trail access. The contract must give the sponsor access to the audit trails generated by the vendor’s system for all regulated data. If the vendor’s system processes clinical trial data, the sponsor needs to be able to produce complete audit trails for that processing in the event of an inspection.
Model change notification and approval. AI models change — vendors update them, retrain them, improve them. A model change that alters the output for the same input is a material change that could affect the integrity of the clinical trial data. Contracts must require the vendor to notify the sponsor of any material model changes and give the sponsor the right to approve changes before they are deployed in the trial. This mirrors the change control requirements that apply to all computerized systems used in clinical trials.
Version locking or equivalence documentation. Related to the above: during the conduct of a trial, the AI tool should be version-locked, or the sponsor needs documentation that any updated version produces equivalent outputs to the version in use at trial initiation. FDA expects consistency in the analytical approach across a trial — introducing a model update mid-trial creates a data integrity question that inspectors will pursue.
Inspection cooperation. The contract must include an obligation on the vendor to cooperate with FDA inspections, including providing access to documentation, systems, and personnel as needed to respond to inspection requests. Without this provision, a sponsor facing an inspection of a vendor-provided AI tool has no contractual basis to demand the vendor’s participation.
Indemnification for AI-specific failures. Standard software indemnification provisions typically cover misappropriation claims and service unavailability. They do not specifically address the scenario where an AI model produces incorrect outputs that contribute to a data integrity finding, a protocol deviation, or a regulatory action. Clinical trial AI contracts should include indemnification provisions that specifically address AI failure modes — including systematic model errors, bias-related failures, and outputs that are inconsistent with validated performance.
Data ownership and return. If the trial terminates, if the sponsor changes vendors, or if the product application is rejected, the sponsor needs to be able to produce complete trial records. Contracts must address data ownership, data return or destruction on contract termination, and the sponsor’s ability to access and export all trial-related data from the vendor’s systems.
The Sponsor Cannot Delegate Responsibility
The foundational principle running through all of this is that regulatory responsibility for a clinical trial cannot be contracted away. A sponsor that uses a vendor’s AI tool and then faces an inspection cannot point to the vendor and say the responsibility was theirs. The sponsor is responsible for every aspect of the trial’s conduct, including the validation and oversight of AI tools used in that conduct.
This means the sponsor needs to be able to independently assess whether each AI tool it uses is fit for purpose. That assessment cannot be a rubber stamp on the vendor’s own assurances — it must be documented, risk-proportionate oversight. For high-risk applications — AI tools that directly generate primary efficacy or safety data — that oversight needs to be substantial.
A recent article in Clinical Leader put it directly: the sponsor remains fully liable for protocol quality, enrollment diversity, and regulatory compliance, yet AI tools diffuse the decision-making process across opaque algorithms and vendor systems. That diffusion is exactly the problem that FDA’s credibility framework is designed to address.
Practical Steps for Sponsors
Create an AI use register. Document every AI tool used in each trial, what it does, who is responsible for it, and what validation has been performed. This is the document that gets reviewed when an inspection opens.
Triage by risk. Apply more rigorous validation and documentation requirements to AI tools that directly generate regulated data than to tools that support internal workflow or administrative functions.
Retrofit existing vendor contracts. Review current vendor agreements for the provisions described above. Many will be inadequate. Negotiate amendments before the tools go live in a trial; it is much harder to add these provisions after a vendor relationship is established.
Test your audit trail. Before an FDA inspection, conduct a dry run: pick a regulated AI output at random and trace it from the final submission document back through every step to the raw input. Can you do it? If not, identify the gap and close it.
Document AI limitations and how they were managed. FDA does not expect perfection from AI tools. It expects transparency about limitations and evidence that those limitations were managed. If an AI tool has known edge cases or failure modes, document how those were mitigated in the trial setting.
The clinical trial environment has never been tolerant of documentation gaps. Adding AI to that environment does not reduce the documentation burden — it adds new dimensions to it. Companies that build robust AI governance into their clinical operations now will be in a substantially stronger position, both at inspection and in the event of litigation, than those that treat audit readiness as someone else’s problem.
This post is for general informational purposes only and does not constitute legal advice. Reading this post does not create an attorney-client relationship. If you have questions about your specific situation, consult a qualified attorney.